secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2026-08-12T20:14:40+00:00
Accession:  0001104659-26-094886
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q2 revenue $7.3M, down 15% YoY; net loss narrows; Genentech partnership signed
--------------------------------------------------------------------------------

- Q2 2026 total revenue $7.3M, down 15% YoY; core revenue $6.5M (-21%), SPL revenue $0.8M.
- Net loss $8.9M vs $12.4M loss in Q2 2025; operating expenses down to $15.8M.
- Cash and investments $141.9M at June 30, 2026; repurchased ~$5.5M under $10M program.
- Reiterates FY2026 guidance: revenue $30-32M (core $25-27M, SPL ~$5M); cash ≥$130.5M.
- In July 2026 signed first multi-platform technology license partnership with Genentech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000110465926094886/0001104659-26-094886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000110465926094886/mxct-20260812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-094886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer